Angela Mastronuzzi: Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma
Angela Mastronuzzi, President of AIOEP, shared a post on LinkedIn about a recent paper by her and colleagues published in Nature Medicine:
” ‘Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma’ out with Nature Medicine published by Nature Portfolio.
Allogeneic chimeric antigen receptor (CAR) T cells targeting disialoganglioside-GD2 (ALLO_GD2-CART01) could be a therapeutic option for patients with relapsed or refractory, high-risk neuroblastoma (r/r HR-NB) whose tumors did not respond to autologous GD2-CART01 or who have profound lymphopenia.
We present a case series of five children with HR-NB refractory to more than three different lines of therapy who received ALLO_GD2-CART01 in a hospital exemption setting.”
“Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma”
Authors: Concetta Quintarelli, Francesca Del Bufalo, Maria Antonietta De Ioris, Angela Mastronuzzi, Biagio De Angelis, Franco Locatelli et al.
More posts featuring Angela Mastronuzzi.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023